| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2874- | HNK, | Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9 |
| - | in-vitro, | Lung, | H1299 |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2897- | HNK, | Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells |
| - | in-vitro, | Lung, | PC9 | - | in-vitro, | Lung, | A549 |
| 2898- | HNK, | Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | BC, | MGC803 | - | in-vitro, | GC, | SGC-7901 |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 7469- | Hops, | CHEMOPREVENTIVE PROPERTIES OF SPENT HOPS (HUMULUS LUPULUS L.) EXTRACT AGAINST ANGIOGENESIS, INVASION AND MIGRATION OF COLORECTAL CANCER CELLS |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | HT29 |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| 7569- | HYP, | Inhibitory effects of hyperoside on lung cancer by inducing apoptosis and suppressing inflammatory response via caspase-3 and NF-κB signaling pathway |
| - | vitro+vivo, | Lung, | A549 |
| 7568- | HYP, | PacT, | Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7567- | HYP, | Hyperoside: A review on its sources, biological activities, and molecular mechanisms |
| - | Review, | Var, | NA |
| 7549- | HYP, | Rad, | Study on the mechanism of hyperoside in affecting the biological progression and radiosensitivity of esophageal carcinoma by modulating the STAT3/AKT/ERK pathway |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE150 |
| 7582- | I3C, | Indole-3-Carbinol Promotes Apoptosis and Inhibits the Metastasis of Esophageal Squamous Cell Carcinoma by Downregulating the Wnt/β-Catenin Signaling Pathway |
| - | vitro+vivo, | ESCC, | NA |
| 7584- | I3C, | Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | HCT8 | - | in-vitro, | Liver, | HepG2 |
| 7592- | I3C, | Indole-3-carbinol as a chemopreventive and anti-cancer agent |
| - | Review, | Var, | NA |
| 7809- | IBC, | Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways |
| - | in-vitro, | GC, | MGC803 |
| 7672- | iod, | Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study |
| - | Trial, | BC, | NA |
| 7682- | iod, | Molecular Iodine Induces Anti- and Pro-Neoplastic Effects in Prostate Cancer Models |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7686- | iod, | Molecular Iodine Exhibited Differential Antiproliferative Actions in Progenitor and Stem Populations from Chemoresistant Cancer Cells |
| - | vitro+vivo, | BC, | MCF7 |
| 7699- | IP6, | IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise |
| - | Review, | Var, | NA |
| 7748- | ISL, | GEM, | Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis |
| - | in-vitro, | Lung, | NA |
| 7756- | ISL, | Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 7757- | ISL, | Isoliquiritigenin Suppresses Oral Squamous Cell Carcinoma Progression by Targeting FABP5-Mediated Lipid Metabolism: Association with the circPOLB/miR-548ae-3p/C-MYC Axis |
| - | in-vitro, | Oral, | NA |
| 7783- | ISL, | Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 9253- | ISO, IH, | Progress in the antitumor molecular mechanisms of Isorhamnetin |
| - | Review, | Var, | NA |
| 9244- | ISO, IH, | Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis |
| - | in-vitro, | Bladder, | 5637 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7730- | isoFl, | Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years |
| - | Review, | Var, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7845- | ISQ, | Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| - | vitro+vivo, | Bladder, | NBT-II |
| 9177- | ITCs, | SFN, | Dietary Isothiocyanates: Novel Insights into the Potential for Cancer Prevention and Therapy |
| - | Review, | Var, | NA |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 7994- | itraC, | From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer |
| - | Review, | Pca, | NA |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 974- | JG, | Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 8089- | KAE, | Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | B16-F10 |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 9002- | L-THE, | Effects of theanine on growth of human lung cancer and leukemia cells as well as migration and invasion of human lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | AML, | K562 |
| 9008- | L-THE, | Theanine and cancer: A systematic review of the literature |
| - | Review, | Var, | NA |
| 9004- | L-THE, | L-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid